STAT3 and hepatocellular carcinoma: Contextually, the aberrant activation of JAK2/STAT3 signaling characterizes various malignancies and is implicated in the tumorigenesis, angiogenesis, metastasis, and recurrence of many cancers, including HCC, and particularly those metastatic and/or recurrent cancers that are refractory to the standard chemotherapy [26,27].